药物基因组学和大数据在医疗瘤学:发展和挑战
Loredana G Marcu1,2, David C Marcu3
1UniSA Allied Health and Human Performance, University of South Australia, Adelaide, SA 5001, Australia.
Therapeutic advances in medical oncology
|November 1, 2024
概括
药物基因组学通过分析基因构成来定制癌症治疗,以预测药物反应,最大限度地减少副作用并改善结果. 这种方法解决了医疗瘤学中耐药性和毒性等挑战.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 医学瘤学利用化疗和向药物来治疗癌症,面临着药物耐药性和正常组织毒性等持续挑战.
- 针对患者量身定制的治疗方法对于抵消药物的不良影响至关重要.
- 药物基因组学通过调查遗传变异如何影响药物反应来提供解决方案.
研究的目的:
- 介绍药物基因组学在医疗瘤学的作用,进展和挑战.
- 突出大数据挖掘对于理解药物基因相互作用的重要性.
- 强调需要临床实施药物基因组学,以改善患者的治疗结果.
主要方法:
- 对医学瘤学中药物基因组学现有文献的综述.
- 讨论用于分析药物基因相互作用的大数据挖掘技术.
- 探索临床实施中的挑战.
主要成果:
- 药物基因组学使化学疗法的个性化方法成为可能,旨在尽量减少试错药物管理.
- 大数据挖掘对于揭示药物基因相互作用机制至关重要.
- 国际努力集中在临床实施上,解决数据标准化,道德问题和教育问题.
结论:
- 药物基因组学具有巨大的潜力,可以通过优化药物选择和减少毒性来改变医学瘤学.
- 克服数据,伦理和教育方面的挑战是实现药物基因组学的全部好处的关键.
- 合作方法对于成功将药物基因组学纳入常规癌症护理至关重要.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
8.9K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Genomics
36.0K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
36.0K
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
60
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
60
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
